Erenumab + Placebo
Phase 1Completed 0 watching 0 views this week๐ค Quiet
32
Development Stage
โ
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Vasomotor Symptoms; Hot Flashes
Conditions
Vasomotor Symptoms; Hot Flashes
Trial Timeline
May 13, 2013 โ Mar 11, 2014
NCT ID
NCT01890109About Erenumab + Placebo
Erenumab + Placebo is a phase 1 stage product being developed by Amgen for Vasomotor Symptoms; Hot Flashes. The current trial status is completed. This product is registered under clinical trial identifier NCT01890109. Target conditions include Vasomotor Symptoms; Hot Flashes.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (9)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04252742 | Approved | Completed |
| NCT03812224 | Phase 3 | Completed |
| NCT02575833 | Phase 2 | Completed |
| NCT02483585 | Phase 3 | Completed |
| NCT02456740 | Phase 3 | Completed |
| NCT02066415 | Phase 2 | Completed |
| NCT01890109 | Phase 1 | Completed |
| NCT01723514 | Phase 1 | Completed |
| NCT01688739 | Phase 1 | Completed |
Competing Products
20 competing products in Vasomotor Symptoms; Hot Flashes